Autologous graft versus myeloma: it's not a myth.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30457981.
- Also identified by DOI 10.1172/JCI125431 and PMC identifier 6307964.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Graft-versus-tumor (GVT) effects have been thought to mostly result from allogeneic transplants; however, there is a growing body of research that supports a possible autologous GVT effect. In early clinical studies, a positive correlation between lymphocyte count recovery after autologous transplantation and overall survival has been observed. However, mechanistic studies to identify the mediators of autologous GVT responses have been lacking. In this issue of the JCI, Vuckovic et al. observed a T cell-dependent autologous GVT effect in the Vk*MYC myeloma model. Moreover, the authors showed that CD8+ T cells mediate myeloma control through IFN-γ secretion, which could be further augmented with a CD137 agonist, suggesting a therapeutic approach for enhancing autologous GVT.
Medical subject headings
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma